• Je něco špatně v tomto záznamu ?

Incidental hepatocellular carcinoma: risk factors and long-term outcome after liver transplantation

R. Senkerikova, S. Frankova, J. Sperl, M. Oliverius, E. Kieslichova, H. Filipova, D. Kautznerova, E. Honsova, P. Trunecka, J. Spicak,

. 2014 ; 46 (5) : 1426-9.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc15014215

BACKGROUND: Orthotopic liver transplantation (OLT) currently represents the treatment of choice for early hepatocellular carcinoma (HCC). Preoperatively known HCC (pkHCC) is diagnosed via imaging methods before OLT or before HCC is found postoperatively in the liver explant, denoted as incidental HCC (iHCC). The aim of this study was a comprehensive analysis of the post-transplantation survival of patients with iHCC and the identification of risk factors of iHCC occurrence in cirrhotic liver. METHODS: We retrospectively reviewed 33 adult cirrhotic patients with incidentally found HCC, comparing them with 606 tumor-free adult cirrhotic patients with end-stage liver disease (group Ci) who underwent OLT in our center from January 1995 to August 2012. Within the same period, a total of 84 patients underwent transplantation for pkHCC. We compared post-transplantation survivals of iHCC, Ci, and pkHCC patients. In the group of cirrhotic patients (Ci + iHCC), we searched for risk factors of iHCC occurrence. RESULTS: There was no difference in sex, Model for End-Stage Liver Disease score, and time spent on the waiting list in either group. In the multivariate analysis we identified age >57 years (odds ratio [OR], 3.37; 95% confidence interval [CI], 1.75-8.14; P < .001), hepatitis C virus or alcoholic liver disease (OR, 3.89; 95% CI, 1.42-10.7; P < .001), and alpha-fetoprotein level >6.4 μg/L (OR, 6.65; 95% CI, 2.82-15.7; P = .002) to be independent predictors of iHCC occurrence. Both the 1-, 3-, and 5-year overall survival (OS) and the 1-, 3- and 5-year recurrence-free survival (RFS) differed in iHCC patients compared with the Ci group (iHCC: OS 79%, 72%, and 68%, respectively; RFS 79%, 72%, and 63%, respectively; vs Ci: OS = RFS: 93%, 94%, and 87%, respectively; P < .001). CONCLUSIONS: The survival of iHCC patients is worse than in tumor-free cirrhotic patients, but similar to pkHCC patients. The independent risk factors for iHCC occurrence in cirrhotic liver are age, hepatitis C virus, or alcoholic liver disease etiology of liver cirrhosis and alpha-fetoprotein level.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15014215
003      
CZ-PrNML
005      
20191023085638.0
007      
ta
008      
150420s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.transproceed.2014.03.010 $2 doi
035    __
$a (PubMed)24935308
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Senkerikova, R $u Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
245    10
$a Incidental hepatocellular carcinoma: risk factors and long-term outcome after liver transplantation / $c R. Senkerikova, S. Frankova, J. Sperl, M. Oliverius, E. Kieslichova, H. Filipova, D. Kautznerova, E. Honsova, P. Trunecka, J. Spicak,
520    9_
$a BACKGROUND: Orthotopic liver transplantation (OLT) currently represents the treatment of choice for early hepatocellular carcinoma (HCC). Preoperatively known HCC (pkHCC) is diagnosed via imaging methods before OLT or before HCC is found postoperatively in the liver explant, denoted as incidental HCC (iHCC). The aim of this study was a comprehensive analysis of the post-transplantation survival of patients with iHCC and the identification of risk factors of iHCC occurrence in cirrhotic liver. METHODS: We retrospectively reviewed 33 adult cirrhotic patients with incidentally found HCC, comparing them with 606 tumor-free adult cirrhotic patients with end-stage liver disease (group Ci) who underwent OLT in our center from January 1995 to August 2012. Within the same period, a total of 84 patients underwent transplantation for pkHCC. We compared post-transplantation survivals of iHCC, Ci, and pkHCC patients. In the group of cirrhotic patients (Ci + iHCC), we searched for risk factors of iHCC occurrence. RESULTS: There was no difference in sex, Model for End-Stage Liver Disease score, and time spent on the waiting list in either group. In the multivariate analysis we identified age >57 years (odds ratio [OR], 3.37; 95% confidence interval [CI], 1.75-8.14; P < .001), hepatitis C virus or alcoholic liver disease (OR, 3.89; 95% CI, 1.42-10.7; P < .001), and alpha-fetoprotein level >6.4 μg/L (OR, 6.65; 95% CI, 2.82-15.7; P = .002) to be independent predictors of iHCC occurrence. Both the 1-, 3-, and 5-year overall survival (OS) and the 1-, 3- and 5-year recurrence-free survival (RFS) differed in iHCC patients compared with the Ci group (iHCC: OS 79%, 72%, and 68%, respectively; RFS 79%, 72%, and 63%, respectively; vs Ci: OS = RFS: 93%, 94%, and 87%, respectively; P < .001). CONCLUSIONS: The survival of iHCC patients is worse than in tumor-free cirrhotic patients, but similar to pkHCC patients. The independent risk factors for iHCC occurrence in cirrhotic liver are age, hepatitis C virus, or alcoholic liver disease etiology of liver cirrhosis and alpha-fetoprotein level.
650    _2
$a dospělí $7 D000328
650    _2
$a hepatocelulární karcinom $x diagnóza $7 D006528
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    12
$a náhodný nález $7 D033162
650    _2
$a jaterní cirhóza $x chirurgie $7 D008103
650    _2
$a nádory jater $x diagnóza $7 D008113
650    12
$a transplantace jater $7 D016031
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a rizikové faktory $7 D012307
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
700    1_
$a Frankova, S $u Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. Electronic address: sona.frankova@ikem.cz.
700    1_
$a Sperl, J $u Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Oliverius, M $u Department of Transplant Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Kieslichova, E $u Department of Anesthesiology and Resuscitation, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Filipová, Helena $7 xx0241075 $u Department of Radiodiagnostic and Interventional Radiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Kautznerova, D $u Department of Radiodiagnostic and Interventional Radiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Honsova, E $u Department of Clinical and Transplant Pathology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Trunecka, P $u Transplantacenter, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Spicak, J $u Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
773    0_
$w MED00004556 $t Transplantation proceedings $x 1873-2623 $g Roč. 46, č. 5 (2014), s. 1426-9
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24935308 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150420 $b ABA008
991    __
$a 20191023090113 $b ABA008
999    __
$a ok $b bmc $g 1071796 $s 897093
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 46 $c 5 $d 1426-9 $i 1873-2623 $m Transplantation proceedings $n Transplant Proc $x MED00004556
LZP    __
$a Pubmed-20150420

Najít záznam

Citační ukazatele

Možnosti archivace